CMS Declines To Change Zevalin And Bexxar Off-Label Coverage Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
There is "insufficient evidence" to change current policy on off-label use of Biogen Idec's Zevalin and GSK's Bexxar in non-Hodgkin's lymphoma, the agency says in a proposed decision memo. CMS directs Medicare contractors to continue providing coverage for medically accepted off-label indications.